Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PNP | P00491 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3923325 | 0.85 | GAA (0.45) | GAAMAPTPKMKDM4ETDP1 | |
| SCHEMBL870860 | 0.79 | PI4KA (0.52) | GAAMAPTPKMKDM4ETDP1 | |
| SCHEMBL26968483 | 0.78 | ADORA3 (0.46) | GAAMAPTPKMKDM4ETDP1 | |
| SCHEMBL24377312 | 0.77 | MPO (0.41) | GAAMAPTNPC1ALDH1A1RAB9A | |
| SCHEMBL19996855 | 0.77 | MPO (0.41) | GAAMAPTNPC1ALDH1A1RAB9A | |
| SCHEMBL1859066 | 0.77 | POLB (0.53) | GAAKDM4EALDH1A1KMT2A | |
| SCHEMBL1669717 | 0.76 | HSP90AA1 (0.45) | PKMNPC1ALDH1A1RAB9AKMT2A | |
| SCHEMBL4849398 | 0.75 | HSP90AA1 (0.48) | ALDH1A1KMT2A | |
| SCHEMBL26968335 | 0.75 | ADORA2A (0.51) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL16347480 | 0.72 | CYP1A2 (0.49) | MAPTKDM4ETDP1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926321-B2 | Hsp90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160310497-A1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2016-10-27 | — | — | US | disclosed |
| US-20160264577-A1 | HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2016-09-15 | — | — | US | disclosed |
| US-9346808-B2 | Hsp90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2016-05-24 | — | — | US | disclosed |
| US-9328114-B2 | Hsp90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2016-05-03 | — | — | US | disclosed |
| US-20120208806-A1 | Hsp90 Inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264577-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AB2P | GAA 310/4885MAPT 2557/4885PKM 2777/4885 |
| US-20120208806-A1 | Hsp90 Inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | GAA 289/4885MAPT 2025/4885PKM 3530/4885 |
| US-20160310497-A1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | XDH, HSP90B1, HSP90AA1 | GAA 345/4885MAPT 3907/4885PKM 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.